LSE-AIM$RNLXY
Renalytix Plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Headline financials
Revenue & EPS history
Renalytix · Revenue · Quarterly
$459K
Q1 2024-52.6%vs Q1 2023
Revenue by segment
Renalytix · $1.2M total across 2 segments · Q2 2023
- KidneyIntelX$1M—83.3%
- Pharmaceutical Services$200K—16.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2024
-11.1%
Avg return
Earnings day
-16.1%
Avg return
5 days after
-20.5%
Avg return
30 days after
19%
3 / 16 earnings
Positive
+13.8%
Q1 2023
Best reaction
-37.4%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -8.1% | -25.2% | -40.5% | |
| Q1 2025 | -8.1% | -25.2% | -40.5% | |
| Q3 2024 | -4.1% | -22.4% | -23.6% | |
| Q2 2024 | -37.4% | -38.0% | -28.9% | |
| Q1 2024 | +3.3% | -16.9% | -34.4% | |
| Q4 2023 | -21.9% | -17.9% | -44.4% | |
| Q2 2023 | -21.9% | -17.9% | -44.4% | |
| Q3 2023 | -5.7% | -3.2% | +46.3% | |
| Q1 2023 | +13.8% | +16.0% | -0.5% | |
| Q4 2022 | +6.7% | -10.2% | +21.6% | |
| Q3 2021 | -37.3% | -41.3% | -37.5% | |
| Q3 2022 | -37.3% | -41.3% | -37.5% | |
| Q2 2022 | -9.1% | -2.3% | -20.0% | |
| Q1 2022 | -9.1% | -2.3% | -20.0% | |
| Q4 2021 | -0.7% | -3.9% | -26.2% | |
| Q4 2020 | -0.8% | -6.0% | +1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro